Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Medplus Health Services's 3-Year RORE % for the quarter that ended in Jun. 2026 was 28.89%.
The industry rank for Medplus Health Services's 3-Year RORE % or its related term are showing as below:
NSE:MEDPLUS's 3-Year RORE % is ranked better than 79.57% of 602
companies
in the Healthcare Providers & Services industry
Industry Median: 0.195
vs NSE:MEDPLUS: 28.89
Medplus Health Services (NSE:MEDPLUS) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Medplus Health Services 3-Year RORE % Related Terms
Medplus Health Services 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medplus Health Services 3-Year RORE % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Medplus Health Services's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medplus Health Services 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medplus Health Services's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Medplus Health Services's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 3-year before.
Medplus Health Services (NSE:MEDPLUS) has a 3-Year RORE % of 28.89 as of Jun. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Medplus Health Services and its competitors. According to the industry distribution chart, Medplus Health Services ranks #123 out of 602 companies in the Healthcare Providers & Services industry, placing it in the top 20.4%.
Is Medplus Health Services' 3-Year RORE % too high?
Medplus Health Services' current 3-Year RORE % is 28.89. The Healthcare Providers & Services industry median 3-Year RORE % is 0.20. Medplus Health Services' value of 28.89 is 14715.4% above this industry median. Based on the distribution chart, Medplus Health Services ranks #123 out of 602 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Medplus Health Services has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medplus Health Services' 3-Year RORE % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Medplus Health Services ranks #123 out of 602 companies for 3-Year RORE %. This places Medplus Health Services in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 0.20. Medplus Health Services' value of 28.89 is 14715.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.20, based on 602 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medplus Health Services's current 3-Year RORE % of 28.89 is 14715.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Medplus Health Services and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medplus Health Services's current 3-Year RORE % is 28.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medplus Health Services stock overvalued right now?
Based on GuruFocus' analysis, Medplus Health Services (NSE:MEDPLUS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹952.31, compared to a current price of ₹691.95 — trading 27.3% below its estimated fair value. The current 3-Year RORE % is 28.89 and 14715.4% above the Healthcare Providers & Services industry median of 0.20. Medplus Health Services' overall GF Score™ is 78/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Medplus Health Services (NSE:MEDPLUS), the current 3-Year RORE % is 28.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medplus Health Services (NSE:MEDPLUS) Overvalued in 2026?
Based on GuruFocus' analysis, Medplus Health Services stock appears to be undervalued.
The current stock price of ₹691.95 is trading 27.3% below its estimated GF Value™ of ₹952.31.
GuruFocus considers Medplus Health Services to be Modestly Undervalued.
Key valuation signals for NSE:MEDPLUS:
3-Year RORE %: 28.89
GF Value™: ₹952.31 vs. price of ₹691.95 (27.3% below fair value)
Industry Position: 14715.4% above the Healthcare Providers & Services median (#123 of 602)
No single metric tells the full story. See the NSE:MEDPLUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medplus Health Services Ltd is a pharmacy retailer. It offers pharmaceutical and wellness products such as medicines, vitamins, medical devices, test kits, and others. The company also offers an omnichannel platform wherein customers can purchase products through stores, place orders over the telephone, online orders, and a Click and Pick facility. Its operating segments include Retail, Diagnostics, and Others.
78GF Score
Get the complete analysis for NSE:MEDPLUS
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDPLUS has been successfully added to your 
